SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation that President Trump will push for federal marijuana rescheduling, potentially boosting the bottom lines of cannabis businesses. The community is buzzing with excitement, anticipating a major run similar to past declassification talks. Some are also discussing target price adjustments, and potential short squeezes.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom ($AVGO) is trending as investors digest the company's earnings report and forward guidance, with community sentiment split between bullish expectations for new ATHs and concerns about potential profit-taking. Discussions revolve around the impact of AI chip revenue and gross margins on the stock's valuation. Analyst target price upgrades are anticipated, adding to the bullish outlook for some traders.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending as investors discuss the potential of Pemvidutide, particularly after FDA AI acceptance for MASH biopsies, which some believe de-risks the asset. Community members are debating the drug's efficacy, safety profile, and potential for a bidding war, while also addressing concerns and FUD spread by bearish voices. Some traders express optimism about upcoming data and potential buyout scenarios, while others highlight risks and past disappointments.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending as investors discuss its recent earnings report, which featured strong international growth offsetting weaker sales in the Americas, and a surprise announcement that the CEO will be stepping down in 2026. A new share buyback program is adding to the bullish sentiment, while analysts are updating their target prices, leading to community speculation about the company's future direction and potential for new leadership.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to a volatile trading day, with community members discussing a potential pump and dump scheme following a recent reverse split and subsequent offering. The stock's price experienced a significant surge and then a sharp decline, leading to debates about the company's fundamentals and market manipulation. Traders are actively speculating on whether MIGI can regain compliance with listing requirements and if further dilution is expected.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

$HOOD is trending amid discussions about November's trading activity and its potential impact, with a specific focus on slowed trading volumes.  The community is debating if this dip is a buying opportunity or a sign of a larger downturn, while also watching for upcoming events and catalysts. Bullish sentiment remains due to expansion plans and potential AI developments, yet concerns persist around Bitcoin correlation and potential market manipulation.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as it showcases its in-house autonomy and AI technology at its first-ever Autonomy and AI Day, with community members discussing the potential impact of new AI-driven features and hardware on the company's future. Investors are weighing Rivian's strategy to develop its own chips and compete with Tesla's autonomous driving capabilities, while some express concerns about the timeline for implementation and the capital expenditure required. There are mixed opinions about the stock's potential, with some anticipating a significant rise and others remain cautious given the company's current financial position.

AXIL Brands, Inc. engages in the manufacture, market, sale and distribution of hearing and audio enhancement, and protection products. It operates through the Hearing Enhancement and Protection, and Hair Care and Skin Care segments. The Hearing Enhancement and Protection segment includes ear buds, earmuffs, ear plugs, outdoor speakers, and ear care items. The Hair Care and Skin Care segment focuses on expanding its business-to-business salon sales through its network of domestic and international distributors. The company was founded on May 21, 2015 and is headquartered in Beverly Hills, CA.

AXIL Brands Inc.

AXIL is trending due to a recently announced national retail distribution agreement with Walmart, sending the stock soaring in premarket trading. Community discussions revolve around the potential for a significant short squeeze and the long-term implications of this deal for the company's brand recognition and revenue. Some traders are wary of potential profit-taking and the stock's history of volatility, while others remain optimistic about further gains.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is gaining attention for its high transaction throughput and compliance-ready architecture, positioning it as a potential backbone for the global financial system. The community is discussing its integration with Bridge, a Stripe company, which facilitates connections to regulated banking streams. Keeta's focus on speed, compliance, and interoperability distinguishes it in the Layer 1 space, attracting interest from investors and institutions alike.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as investors discuss potential impacts from a shift in US-China tech trade policy regarding chip exports, as well as a new partnership with Tata Electronics in India. Community perspectives are mixed, with some anticipating a rise to previous levels and others remaining skeptical amid broader market dynamics and concerns about potential competitive disadvantages. Discussions also include analyst target price updates and speculation about large options positions influencing near-term price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report?

Blueprint Medicines came under pressure from Wall Street on Monday after at least six brokerages downgraded the stock following news of its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sanofi-to-buy-blueprint-medicines-for-up-to-9.5-billion/chkoCYnRbHc">$9.1 billion acquisition</a> by French pharmaceutical giant Sanofi.The stock closed at $127.79 on Monday, up 26.1% for the day. After-hours trading showed a slight decline of 0.1% to $127.67.TD Cowen analyst Marc Frahm lowered the stock rating to ‘Hold’ from ‘Buy’ and established a price target of $130 based on the acquisition terms.&nbsp;JPMorgan reduced its rating to ‘Neutral’ from ‘Overweight’ and adjusted its target price to $129 from $130.Wolfe Research reduced Blueprint's rating to ‘Peer Perform’ from ‘Outperform’ by noting that the deal values Blueprint at $129 per share.&nbsp;Oppenheimer lowered its stock rating to ‘Perform’ from ‘Outperform,’ while describing the agreement as a “solid outcome for shareholders.”Scotiabank reduced its stock rating to ‘Sector Perform’ from ‘Outperform,’ while establishing a target price of $135.&nbsp;Wedbush assigned a $129 target after downgrading Blueprint to ‘Neutral’, while Needham downgraded it to ‘Hold.’Blueprint Medicines shareholders will receive one non-tradeable contingent value right (CVR), entitling them to two potential milestone payments of $2 and $4 per CVR, contingent on&nbsp;achieving future development and regulatory milestones for BLU-808.BLU-808 is an investigational oral inhibitor targeting wild-type KIT, which plays a role in mast cell activation involved in inflammatory diseases, including chronic urticaria.Including these potential payments, the total equity value of the Sanofi acquisition rises to approximately $9.5 billion on a fully diluted basis.Sanofi CEO Paul Hudson said this acquisition moves their rare and immunology portfolios forward.Sanofi’s earnings and gross margin will benefit from the transaction after 2026, while the company’s financial guidance for 2025 remains unaffected.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user described the price movement as a positive surprise, reporting a roughly 30% gain on their investment,&nbsp;noting this was better than recent returns on SpringWorks Therapeutics, but lower than several earlier buyouts this year.&nbsp;<stembedurl>https://stocktwits.com/Jackie_O_/message/616535057</stembedurl>Another user said that increased European pharma purchases of U.S. companies might be a strategy to gain favor with the Trump administration.<stembedurl>https://stocktwits.com/ajmore/message/616481051</stembedurl>Blueprint Medicines’&nbsp;stock has risen 46.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Blueprint Medicines company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Blueprint Medicines Stock  Lands Several Downgrades After Sanofi’s Buyout Deal, But Retail Bulls Keep The Faith

Analysts revised price targets near the deal’s $129-per-share valuation.

Equity

Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines 

Shares of Blueprint Medicines Corporation (BPMC) traded 26% higher in pre-market on Monday after French pharmaceutical company Sanofi (SNY) <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-02-05-00-00-3091541">announced</a> that it would acquire Blueprint in a bid to expand its rare immunological disease portfolio.Under the terms of the deal, Sanofi will pay $129 per share in cash at closing, representing an equity value of approximately $9.1 billion.The upfront purchase price represents a 27% premium to Blueprint’s closing price on Friday of $101.35.In addition, Blueprint shareholders will receive one non-tradable contingent value right (CVR), which will entitle them to receive two potential milestone payments of $2 and $4 per CVR for the achievement of future milestones for BLU-808, an investigational therapy with the potential to treat a broad range of diseases in immunology.The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis, Sanofi said. The firm added that it expects the transaction to be completed in the third quarter of 2025.The acquisition includes Ayvakit or Ayvakyt (Avapritinib), the only approved medicine for rare immunology diseases, advanced and indolent systemic mastocytosis (ASM &amp; ISM), in addition to Elenestinib, an investigational medicine for systemic mastocytosis, as well as BLU-808.Sanofi CEO Paul Hudson said that the company retains a “sizeable capacity” for further acquisitions. The firm expects the Blueprint acquisition not to have a significant impact on its financial guidance for 2025 but to be immediately accretive to gross margin and to business operating income and EPS after 2026.Last month, Sanofi said it is looking to invest at least $20 billion in the U.S. through 2030. The company also announced it would acquire U.S.-based Vigil Neuroscience, Inc. (VIGL) for about $470 million soon after.On Stocktwits, retail sentiment around Blueprint Medicines Corporation jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_02_at_8_06_38_AM_png_dab4b84360.webp" alt="BPMC's Sentiment Meter and Message Volume as of 8:15 a.m. ET on June 2, 2025 | Source: Stocktwits" width="627" height="66"><figcaption>BPMC's Sentiment Meter and Message Volume as of 8:15 a.m. ET on June 2, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, retail sentiment around Sanofi stayed unmoved within the ‘bullish’ territory while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:630/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_02_at_8_14_54_AM_png_d728df50b2.webp" alt="SNY's Sentiment Meter and Message Volume as of 8:15 a.m. ET on June 2, 2025 | Source: Stocktwits" width="630" height="65"><figcaption>SNY's Sentiment Meter and Message Volume as of 8:15 a.m. ET on June 2, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes U.S. pharmaceutical companies will receive acquisition offers from their European counterparts.<stembedurl>https://stocktwits.com/ajmore/message/616481051</stembedurl>While <a href="https://stocktwits.com/symbol/BPMC">BPMC stock</a> is up by about 16% this year, <a href="https://stocktwits.com/symbol/SNY">SNY stock</a> is up by over 2%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/microsoft-commits-400-million-to-boost-swiss-ai-cloud-ecosystem/chkoUr7RbHb">Microsoft Commits $400M To Boost Swiss AI, Cloud Ecosystem: Retail Mood Stays ‘Bearish’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Photo taken on April 15, 2025 shows the pharmaceutical factory of pharmaceutical company Sanofi in Hangzhou, Zhejiang province, China. (Photo credit should read CFOTO/Future Publishing via Getty Images)

Sanofi To Buy Blueprint Medicines For Up To $9.5B: Retail Sees More Acquisition Offers From European Pharma Companies

Sanofi will pay $129 per share in cash at closing, representing a 27% premium to Blueprint’s closing price on Friday of $101.35.

Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Blueprint Medicines Corp

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

BPMC
Blueprint Medicines Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BPMC News

BPMCBlueprint Medicines Corp